Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Adial Pharmicals, Inc.取得了重要的里程碑，美国证券交易委员会（SEC）宣布其S-3表格自2024年1月24日下午5点起生效。该表格是一份注册声明，允许公司向公众发行各种证券，包括股票和债券。该表格的有效性表明，Adial Pharmicals已经满足了进行证券发行的所有必要监管要求。
Adial Pharmicals, Inc.取得了重要的里程碑，美国证券交易委员会（SEC）宣布其S-3表格自2024年1月24日下午5点起生效。该表格是一份注册声明，允许公司向公众发行各种证券，包括股票和债券。该表格的有效性表明，Adial Pharmicals已经满足了进行证券发行的所有必要监管要求。
有用
没用
